Comparative Pharmacology
Head-to-head clinical analysis: ALLERFED versus CORSYM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLERFED versus CORSYM.
ALLERFED vs CORSYM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction; chlorpheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
Adults: 100 mg orally once daily, taken with water at least 1 hour before meals. Maximum dose 100 mg/day.
None Documented
None Documented
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
The terminal elimination half-life for hydrocodone from the CORSYM formulation is approximately 8-10 hours, reflecting the extended-release profile. This allows for twice-daily dosing. Hydrocodone's half-life in immediate-release forms is about 3-4 hours, so the polistirex complex prolongs absorption. Chlorpheniramine has a half-life of about 20-24 hours in adults, but in the polistirex formulation, its half-life is extended to approximately 18-22 hours, supporting once-daily dosing for the antihistamine component.
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
CORSYM (hydrocodone polistirex and chlorpheniramine polistirex) is an extended-release formulation. Hydrocodone is metabolized primarily in the liver via CYP3A4 and CYP2D6 to norhydrocodone, hydromorphone, and other metabolites. Excretion is predominantly renal (about 90%) as unchanged drug and metabolites, with approximately 10% excreted in feces via biliary elimination. Chlorpheniramine is metabolized in the liver and excreted renally as metabolites (about 70-80%) and unchanged drug (about 10-20%), with minor fecal excretion.
Category C
Category C
Decongestant
Antihistamine/Decongestant